OPKO Health’s fourth-quarter report highlighted positive activities in the face of a net loss of $213.9 million during the most recent quarter. Source: BioSpace

Figuring out the best way to turn down a job offer is a “good” problem to have. If anything, receiving one or multiple job offers gives you a sense of…

Sorrento Therapeutics, Inc. nabbed regulatory approval for ZTlido, a non-opioid pain treatment in the form of a super-sticky patch. Source: BioSpace

Shares of Portola Pharmaceuticals are falling after the company announced a delay of several months for possible regulatory approval of its Factor Xa-inhibitor antidote, AndexXa. Source: BioSpace

Finch Therapeutics closed on an oversubscribed Series B financing worth $36 million. Source: BioSpace

Rubius Therapeutics has closed on an oversubscribed $100 million crossover financing. Source: BioSpace

Mylan N.V. signed a global collaboration and license deal with Revance Therapeutics to develop and market a biosimilar to Botox. Source: BioSpace

Boston-based Gelesis snagged $30 million to support potential manufacturing and commercialization of its anti-obesity drug. Source: BioSpace

With no end to the national opioid crisis in sight, the U.S. Department of Justice announced a plan to form a task force that will target opioid manufacturers and distributors.…

The U.S. Food and Drug Administration stunned the company with a Refusal to File letter regarding its New Drug Application (NDA) for multiple sclerosis treatment ozanimod. Source: BioSpace